Asarina Pharma AB (publ) (ASAP.ST)
SEK 0.03
(-31.03%)
SEK 0.03
(-31.03%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -14.64 Million SEK | 0.32% |
| 2022 | -14.68 Million SEK | 61.64% |
| 2021 | -38.28 Million SEK | 52.97% |
| 2020 | -81.4 Million SEK | -0.46% |
| 2019 | -81.03 Million SEK | -57.05% |
| 2018 | -51.59 Million SEK | -58.61% |
| 2017 | -32.53 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q4 | -2.55 Million SEK | 0.0% |
| 2023 FY | -14.64 Million SEK | 0.32% |
| 2023 Q1 | -4.76 Million SEK | -42.59% |
| 2023 Q2 | -4.76 Million SEK | 0.0% |
| 2023 Q3 | -2.55 Million SEK | 46.3% |
| 2022 Q3 | -3.34 Million SEK | 16.12% |
| 2022 Q1 | -4.02 Million SEK | 45.85% |
| 2022 FY | -14.68 Million SEK | 61.64% |
| 2022 Q4 | -3.34 Million SEK | 0.0% |
| 2022 Q2 | -3.98 Million SEK | 1.07% |
| 2021 Q2 | -16.01 Million SEK | -136.34% |
| 2021 Q3 | -8.06 Million SEK | 49.64% |
| 2021 Q4 | -7.43 Million SEK | 7.82% |
| 2021 FY | -38.28 Million SEK | 52.97% |
| 2021 Q1 | -6.77 Million SEK | 72.8% |
| 2020 Q2 | -17.84 Million SEK | 15.52% |
| 2020 FY | -81.4 Million SEK | -0.46% |
| 2020 Q4 | -24.91 Million SEK | -42.07% |
| 2020 Q3 | -17.53 Million SEK | 1.72% |
| 2020 Q1 | -21.11 Million SEK | -3.69% |
| 2019 Q2 | -28.12 Million SEK | -161.58% |
| 2019 Q1 | -10.75 Million SEK | 47.5% |
| 2019 FY | -81.03 Million SEK | -57.05% |
| 2019 Q4 | -20.36 Million SEK | 6.51% |
| 2019 Q3 | -21.78 Million SEK | 22.55% |
| 2018 Q1 | -5 Million SEK | 32.06% |
| 2018 FY | -51.59 Million SEK | -58.61% |
| 2018 Q4 | -20.48 Million SEK | -39.9% |
| 2018 Q3 | -14.64 Million SEK | -27.62% |
| 2018 Q2 | -11.47 Million SEK | -129.3% |
| 2017 Q4 | -7.36 Million SEK | -107.26% |
| 2017 FY | -32.53 Million SEK | 0.0% |
| 2017 Q1 | -8.88 Million SEK | 0.0% |
| 2017 Q3 | -3.55 Million SEK | 60.0% |
| 2017 Q2 | -8.88 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 96.191% |
| AcouSort AB (publ) | -17.48 Million SEK | 16.281% |
| Active Biotech AB (publ) | -46.48 Million SEK | 68.505% |
| Alzinova AB (publ) | -16.52 Million SEK | 11.391% |
| Amniotics AB (publ) | -29.07 Million SEK | 49.644% |
| BioArctic AB (publ) | 252.64 Million SEK | 105.795% |
| Camurus AB (publ) | 532.35 Million SEK | 102.75% |
| Cantargia AB (publ) | -290.01 Million SEK | 94.952% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 27.305% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 14.367% |
| Genovis AB (publ.) | 54.22 Million SEK | 126.999% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 87.278% |
| Mendus AB (publ) | -100.65 Million SEK | 85.455% |
| Kancera AB (publ) | -65.04 Million SEK | 77.491% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -317.689% |
| LIDDS AB (publ) | -40.67 Million SEK | 64.006% |
| Lipum AB (publ) | -37.25 Million SEK | 60.702% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -18.341% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 181.293% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 10.737% |
| NextCell Pharma AB | -43.17 Million SEK | 66.089% |
| OncoZenge AB (publ) | -15.9 Million SEK | 7.936% |
| Saniona AB (publ) | -81.06 Million SEK | 81.94% |
| Simris Alg AB (publ) | -36.63 Million SEK | 60.038% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 95.446% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 95.284% |
| Xintela AB (publ) | -57.23 Million SEK | 74.423% |
| Ziccum AB (publ) | -21.56 Million SEK | 32.096% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 64.878% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 91.901% |
| CombiGene AB (publ) | -36.3 Million SEK | 59.675% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 90.011% |
| Intervacc AB (publ) | -93.57 Million SEK | 84.355% |
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 94.12% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -1632.544% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | 5.621% |
| Corline Biomedical AB | -1.78 Million SEK | -718.792% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 91.901% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 73.582% |
| Aptahem AB (publ) | -10.1 Million SEK | -44.882% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 89.125% |
| Fluicell AB (publ) | -26.87 Million SEK | 45.534% |
| Biovica International AB (publ) | -126.07 Million SEK | 88.388% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 65.557% |
| Abliva AB (publ) | -96.54 Million SEK | 84.837% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 95.493% |
| 2cureX AB (publ) | -36.36 Million SEK | 59.739% |
| I-Tech AB | 24.43 Million SEK | 159.914% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 98.143% |
| Cyxone AB (publ) | -21.66 Million SEK | 32.413% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 86.184% |
| Biosergen AB | -27.26 Million SEK | 46.305% |
| Nanologica AB (publ) | -69.96 Million SEK | 79.075% |
| SynAct Pharma AB | -224.49 Million SEK | 93.479% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 66.86% |
| BioInvent International AB (publ) | -369.94 Million SEK | 96.043% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 38.884% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 94.224% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -128.992% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 86.801% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -26.578% |